posted mixed Q4 results, with revenue and EBITDA slightly missing estimates. FY26 guidance indicated mid-to high-single-digit revenue growth, seen as conservative. However, Citi and Macquarie remain bullish due to long-term prospects and specialty product investments. FY26 EPS estimates were revised, while FY27 outlook remains intact. The company plans to spend $100 million on US launches of Leqselvi and Unloxcyt.

#FundamentalViews

211 likes·72 comments